Impacts on Postoperative Bleeding of Surgery for Head and Neck Malignancies While Continuing Antithrombotic Agents.

Koji Ushiro, Ryo Asato, Hiroki Ishida, Chisato Chikugo, Yukiko Ito, Takuya Tsuji, Jun Tsuji
Author Information
  1. Koji Ushiro: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. ORCID
  2. Ryo Asato: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  3. Hiroki Ishida: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  4. Chisato Chikugo: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  5. Yukiko Ito: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  6. Takuya Tsuji: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  7. Jun Tsuji: Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Abstract

 Perioperative management of antithrombotic agents may affect bleeding and lead to thromboembolic complications, but there is no consensus on optimal protocol in head and neck surgery.  To explore the effect of antithrombotic agents on postoperative bleeding.  We compared clinical characteristics, type of surgery, antithrombotic agents, continued use of medication or not, and frequency of postoperative bleeding among patients who were receiving antithrombotic therapy at the time of their decision to undergo surgery for head and neck malignancies, from 2008 to 2022.  A total of 168 patients were included. There was no significant difference in the incidence of intraoperative blood loss or postoperative bleeding between the group that underwent surgery while on antithrombotic therapy and those that underwent surgery after antithrombotic therapy was discontinued. In particular, there was no increase in bleeding complications with antiplatelet agents, regardless of the type or number of agents used.  Surgery for head and neck malignancies with continued antiplatelet therapy may not increase bleeding complications, regardless of the type of antiplatelet therapy and even when multiple agents are taken.

Keywords

References

  1. JAMA Intern Med. 2019 Nov 01;179(11):1469-1478 [PMID: 31380891]
  2. Ophthalmology. 2003 Sep;110(9):1784-8 [PMID: 13129878]
  3. N Engl J Med. 2015 Aug 27;373(9):823-33 [PMID: 26095867]
  4. Dig Endosc. 2014 Jan;26(1):1-14 [PMID: 24215155]
  5. Br Dent J. 2007 Oct 13;203(7):389-93 [PMID: 17934422]
  6. JAMA Facial Plast Surg. 2015 Mar-Apr;17(2):103-7 [PMID: 25541679]
  7. J Can Dent Assoc. 2009 Feb;75(1):41 [PMID: 19239742]
  8. Br J Ophthalmol. 2015 Aug;99(8):1025-30 [PMID: 25425711]
  9. Open Cardiovasc Med J. 2016 May 27;10:94-104 [PMID: 27347226]
  10. J Am Heart Assoc. 2020 Mar 3;9(5):e012774 [PMID: 32079478]
  11. Anesthesiology. 2011 Jun;114(6):1289-96 [PMID: 21478735]
  12. Stroke. 2008 Jun;39(6):1740-5 [PMID: 18388341]
  13. Gastrointest Endosc. 2009 Dec;70(6):1060-70 [PMID: 19889407]
  14. Circulation. 2007 Oct 23;116(17):e418-99 [PMID: 17901357]
  15. Hernia. 2011 Feb;15(1):31-5 [PMID: 20890623]

Word Cloud

Created with Highcharts 10.0.0antithromboticbleedingagentssurgerypostoperativetherapyheadneckcomplicationstypeantiplateletmaycontinuedpatientsmalignanciesunderwentincreaseregardless Perioperativemanagementaffectleadthromboembolicconsensusoptimalprotocol Toexploreeffect Wecomparedclinicalcharacteristicsusemedicationfrequencyamongreceivingtimedecisionundergo20082022 Atotal168includedsignificantdifferenceincidenceintraoperativebloodlossgroupdiscontinuedparticularnumberused SurgeryevenmultipletakenImpactsPostoperativeBleedingSurgeryHeadNeckMalignanciesContinuingAntithromboticAgentsagentcomplication

Similar Articles

Cited By